160 related articles for article (PubMed ID: 16845256)
21. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor.
Xiao Z; Théroux P
Circulation; 1998 Jan; 97(3):251-6. PubMed ID: 9462526
[TBL] [Abstract][Full Text] [Related]
22. Bivalirudin: a new promising direct antithrombin.
Bhambhani A; Meier B
Indian Heart J; 2007; 59(3):288-94. PubMed ID: 19124943
[TBL] [Abstract][Full Text] [Related]
23. Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention.
Busch G; Steppich B; Sibbing D; Braun SL; Stein A; Groha P; Schömig A; Kastrati A; von Beckerath N; Ott I
Thromb Haemost; 2009 Feb; 101(2):340-4. PubMed ID: 19190819
[TBL] [Abstract][Full Text] [Related]
24. Direct thrombin inhibitors in cardiac disease.
Weitz JI; Bates ER
Cardiovasc Toxicol; 2003; 3(1):13-25. PubMed ID: 12668887
[TBL] [Abstract][Full Text] [Related]
25. Bivalirudin for patients with acute coronary syndromes.
Stone GW; McLaurin BT; Cox DA; Bertrand ME; Lincoff AM; Moses JW; White HD; Pocock SJ; Ware JH; Feit F; Colombo A; Aylward PE; Cequier AR; Darius H; Desmet W; Ebrahimi R; Hamon M; Rasmussen LH; Rupprecht HJ; Hoekstra J; Mehran R; Ohman EM;
N Engl J Med; 2006 Nov; 355(21):2203-16. PubMed ID: 17124018
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis of antithrombotic therapy in nonurgent percutaneous coronary intervention.
Summers KM; Holdford DA; Crouch MA
Pharmacotherapy; 2006 May; 26(5):609-18. PubMed ID: 16637790
[TBL] [Abstract][Full Text] [Related]
27. Comparative antithrombotic effects of magnesium sulfate and the platelet glycoprotein IIb/IIIa inhibitors tirofiban and eptifibatide in a canine model of stent thrombosis.
Rukshin V; Shah PK; Cercek B; Finkelstein A; Tsang V; Kaul S
Circulation; 2002 Apr; 105(16):1970-5. PubMed ID: 11997285
[TBL] [Abstract][Full Text] [Related]
28. Dichotomous effects of exposure to bivalirudin in patients undergoing percutaneous coronary intervention on protease-activated receptor-mediated platelet activation.
Holinstat M; Colowick NE; Hudson WJ; Blakemore D; Chen Q; Hamm HE; Cleator JH
J Thromb Thrombolysis; 2013 Feb; 35(2):209-22. PubMed ID: 23054462
[TBL] [Abstract][Full Text] [Related]
29. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro.
Nielsen VG; Steenwyk BL; Gurley WQ; Pereira SJ; Lell WA; Kirklin JK
J Heart Lung Transplant; 2006 Jun; 25(6):653-63. PubMed ID: 16730571
[TBL] [Abstract][Full Text] [Related]
30. Clinical pharmacology of bivalirudin.
Reed MD; Bell D
Pharmacotherapy; 2002 Jun; 22(6 Pt 2):105S-111S. PubMed ID: 12064567
[TBL] [Abstract][Full Text] [Related]
31. Pretreatment with ticagrelor may offset additional inhibition of platelet and coagulation activation with bivalirudin compared to heparin during primary percutaneous coronary intervention.
Venetsanos D; Lindahl TL; Lawesson SS; Gustafsson KM; Wallen H; Erlinge D; Swahn E; Alfredsson J
Thromb Res; 2018 Nov; 171():38-44. PubMed ID: 30248659
[TBL] [Abstract][Full Text] [Related]
32. Heparin resistance in acute coronary syndromes.
Rich JD; Maraganore JM; Young E; Lidon RM; Adelman B; Bourdon P; Charenkavanich S; Hirsh J; Theroux P; Cannon CP
J Thromb Thrombolysis; 2007 Apr; 23(2):93-100. PubMed ID: 17221324
[TBL] [Abstract][Full Text] [Related]
33. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors.
Bangalore S; Toklu B; Kotwal A; Volodarskiy A; Sharma S; Kirtane AJ; Feit F
BMJ; 2014 Nov; 349():g6419. PubMed ID: 25389143
[TBL] [Abstract][Full Text] [Related]
34. Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils.
Li G; Keenan AC; Young JC; Hall MJ; Pamuklar Z; Ohman EM; Steinhubl SR; Smyth SS
Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1850-6. PubMed ID: 17525363
[TBL] [Abstract][Full Text] [Related]
35. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin.
Bates SM; Weitz JI
Am J Cardiol; 1998 Oct; 82(8B):12P-18P. PubMed ID: 9809887
[TBL] [Abstract][Full Text] [Related]
36. New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?
Esteve-Pastor MA; Hernández-Romero D; Valdés M; Marín F
Molecules; 2016 Feb; 21(3):284. PubMed ID: 26927051
[TBL] [Abstract][Full Text] [Related]
37. Platelet protagonist/antagonist: understanding the distinguishing characteristics of anticoagulants.
Schneider DJ
Rev Cardiovasc Med; 2006; 7 Suppl 3():S3-11. PubMed ID: 17224882
[TBL] [Abstract][Full Text] [Related]
38. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes.
Pinto DS; Stone GW; Shi C; Dunn ES; Reynolds MR; York M; Walczak J; Berezin RH; Mehran R; McLaurin BT; Cox DA; Ohman EM; Lincoff AM; Cohen DJ;
J Am Coll Cardiol; 2008 Nov; 52(22):1758-68. PubMed ID: 19022155
[TBL] [Abstract][Full Text] [Related]
39. Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry.
Hibbert B; MacDougall A; Labinaz M; O'Brien ER; So DY; Dick A; Glover C; Froeschl M; Marquis JF; Wells GA; Blondeau M; Le May MR
Circ Cardiovasc Interv; 2012 Dec; 5(6):805-12. PubMed ID: 23149331
[TBL] [Abstract][Full Text] [Related]
40. Influence of bivalirudin on tissue factor-triggered coagulation.
Butenas S; Orfeo T; Brummel-Ziedins KE; Mann KG
Blood Coagul Fibrinolysis; 2007 Jul; 18(5):407-14. PubMed ID: 17581314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
